Serum sCD26 for colorectal cancer screening in family-risk individuals: Comparison with faecal immunochemical test

British Journal of Cancer

Volumn 112, Issue 2, 2015, Pages 375-381

  Otero Estevez O ^a   De Chiara, L ^a   Rodriguez Berrocal F J ^a   Paez De La Cadena M ^a   Cubiella, J ^b   Castro, I ^b   Gonzalez Mao, C ^c   Hernandez, V ^c   Martinez Zorzano V S ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b Department of Gastroenterology Complexo Hospitalario Universitario de Ourense ^*  (Spain)

^c UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

Colorectal cancer screening; Faecal immunochemical test; Family risk; Serum sCD26

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; SOLUBLE CD26; UNCLASSIFIED DRUG; DPP4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; FIRST DEGREE RELATIVE; HUMAN; IMMUNOCHEMISTRY; MALE; OCCULT BLOOD TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; ADENOMA; BLOOD; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EARLY DIAGNOSIS; ENZYMOLOGY; IMMUNOASSAY; MIDDLE AGED; OCCULT BLOOD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DIPEPTIDYL PEPTIDASE 4; DOUBLE-BLIND METHOD; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; OCCULT BLOOD; PROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84921972668     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.605     Document Type: Article

References (34)

1. Barnert J, Messmann H (2009) Diagnosis and management of lower gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol 6: 637-646.
2. Brenner H, Kloor M, Pox CP (2014) Colorectal cancer. Lancet 383: 1490-1502.
3. Bünger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, Fitzgerald SP, Toner V, McAleer D, Gemoll T, Laubert T, Büning J, Fellermann K, Bruch HP, Roblick UJ, Brenner H, von Eggeling F, Habermann JK (2012) A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer 12: 393-405.
4. Burt RW, Barthel JS, Dunn KB, David DS, Drelichman E, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton SR, Ismail MK, Jasperson K, Lazenby AJ, Lynch PM, Martin Jr EW, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D. NCCN (2010) NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 8: 8-61.
5. Butterworth AS, Higgins JP, Pharoah P (2006) Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 42: 216-227.
6. Castro I, Cubiella J, Rivera C, González-Mao C, Vega P, Soto S, Hernandez V, Iglesias F, Teresa Alves M, Bujanda L, Fernández-Seara J (2014) Fecal immunochemical test accuracy in familial risk colorectal cancer screening. Int J Cancer 134: 367-375.
7. Chiu HM, Lee YC, Tu CH, Chen CC, Tseng PH, Liang JT, Shun CT, Lin JT, Wu MS (2013) Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol 11: 832-838.
8. Ciatto S, Martinelli F, Castiglione G, Mantellini P, Rubeca T, Grazzini G, Bonanomi AG, Confortini M, Zappa M (2007) Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer 96: 218-221.
9. Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ, de la Cadena MP (2000) Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 83: 1139-1146.
10. Cordero OJ, Salgado FJ, Nogueira M (2009) On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 58: 1723-1747.
11. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Cordero OJ, Martínez-Ares D, Páez de la Cadena M (2010) Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer 10: 333-342.
12. Del Vecchio Blanco G, Cretella M, Paoluzi OA, Caruso A, Mannisi E, Servadei F, Romeo S, Grasso E, Sileri P, Giannelli M, Biancone L, Palmieri G, Pallone F (2013) Adenoma, advanced adenoma and colorectal cancer prevalence in asymptomatic 40- to 49-year-old subjects with a first-degree family history of colorectal cancer. Colorectal Dis 15: 1093-1099.
13. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474.
14. Gimeno-García AZ, Quintero E, Nicolás-Pérez D, Hernández-Guerra M, Parra-Blanco A, Jiménez-Sosa A (2009) Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. Eur J Gastroenterol Hepatol 21: 1062-1067.
15. Gorrell MD, Gysbers V, McCaughan GW (2001) CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 54: 249-264.
16. Halloran SP, Launoy G, Zappa M. International Agency for Research on Cancer (2012) European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Faecal occult blood testing. Endoscopy 44: SE65-SE87.
17. Haug U, Knudsen AB, Brenner H, Kuntz KM (2011) Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Rev Mol Diagn 11: 605-616.
18. Houlston RS, Murday V, Harocopos C, Williams CB, Slack J (1990) Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. BMJ 301: 366-368.
19. Jover R, Herráiz M, Alarcón O, Brullet E, Bujanda L, Bustamante M, Campo R, Carreño R, Castells A, Cubiella J, García-Iglesias P, Hervás AJ, Menchén P, Ono A, Panadés A, Parra-Blanco A, Pellisé M, Ponce M, Quintero E, Reñé JM, Sánchez del Río A, Seoane A, Serradesanferm A, Soriano Izquierdo A, Vázquez Sequeiros E. Spanish Society of GastroenterologySpanish Society of Gastrointestinal Endoscopy Working Group (2012) Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 44: 444-451.
20. Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, de Bruïne AP, Meijer GA, Janssen JB, van Engeland M, Stockbrügger RW, Masclee AA (2011) Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) 4: 1563-1571.
21. Kristinsson J, Nygaard K, Aadland E, Barstad S, Sauar J, Hofstad B, Stray N, Stallemo A, Haug B, Ugstad M, Tøn H, Fuglerud P (2001) Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II. Digestion 64: 104-110.
22. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y (2005) A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129: 422-428.
23. Ng SC, Ching JY, Chan V, Wong MC, Suen BY, Hirai HW, Lam TY, Lau JY, Ng SS, Wu JC, Chan FK, Sung JJ (2013) Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer. Aliment Pharmacol Ther 38: 835-841.
24. Rozen P, Comaneshter D, Levi Z, Hazazi R, Vilkin A, Maoz E, Birkenfeld S, Niv Y (2010) Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 116: 2115-2125.
25. Shimwell NJ, Wei W, Wilson S, Wakelam MJ, Ismail T, Iqbal T, Johnson PJ, Martin A, Ward DG (2010) Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomark 7: 123-132.
26. Stegeman I, de Wijkerslooth TR, Stoop EM, van Leerdam ME, Dekker E, van Ballegooijen M, Kuipers EJ, Fockens P, Kraaijenhagen RA, Bossuyt PM (2014) Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut 63: 466-471.
27. Sulz MC, Meyenberger C, Sawatzki M (2014) How is the increased risk of colorectal cancer in first-degree relatives of patients communicated? Eur J Gastroenterol Hepatol 26: 222-228.
28. Tao S, Haug U, Kuhn K, Brenner H (2012) Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for noninvasive colorectal cancer screening. Br J Cancer 106: 1424-1430.
29. Terhaar sive Droste JS, van Turenhout ST, Oort FA, van der Hulst RW, Steeman VA, Coblijn U, van der Eem L, Duijkers R, Bouman AA, Meijer GA, Depla AC, Scholten P, Loffeld RJ, Coupé VM, Mulder CJ (2012) Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. BMC Gastroenterol 12: 94-102.
30. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB, Dekker E (2008) Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135: 82-90.
31. von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, Steele RJ, Vieth M, Aabakken L, Altenhofen L, Ancelle-Park R, Antoljak N, Anttila A, Armaroli P, Arrossi S, Austoker J, Banzi R, Bellisario C, Blom J, Brenner H, Bretthauer M, Camargo Cancela M, Costamagna G, Cuzick J, Dai M, Daniel J, Dekker E, Delicata N, Ducarroz S, Erfkamp H, Espinàs JA, Faivre J, Faulds Wood L, Flugelman A, Frkovic-Grazio S, Geller B, Giordano L, Grazzini G, Green J, Hamashima C, Herrmann C, Hewitson P, Hoff G, Holten I, Jover R, Kaminski MF, Kuipers EJ, Kurtinaitis J, Lambert R, Launoy G, Lee W, Leicester R, Leja M, Lieberman D, Lignini T, Lucas E, Lynge E, Mádai S, Marinho J, Maučec Zakotnik J, Minoli G, Monk C, Morais A, Muwonge R, Nadel M, Neamtiu L, Peris Tuser M, Pignone M, Pox C, Primic-Zakelj M, Psaila J, Rabeneck L, Ransohoff D, Rasmussen M, Regula J, Ren J, Rennert G, Rey J, Riddell RH, Risio M, Rodrigues V, Saito H, Sauvaget C, Scharpantgen A, Schmiegel W, Senore C, Siddiqi M, Sighoko D, Smith R, Smith S, Suchanek S, Suonio E, Tong W, Törnberg S, Van Cutsem E, Vignatelli L, Villain P, Voti L, Watanabe H, Watson J, Winawer S, Young G, Zaksas V, Zappa M, Valori R (2013) European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 45: 51-59.
32. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C. Gastrointestinal Consortium Panel (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 124: 544-560.
33. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrell MD (2010) The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 277: 1126-1144.
34. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD (2012) Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 366 : 687-696.